Voruciclib blocks a molecule called cyclin-dependent Kinase (CDK), which then decreases the amount of another molecule, called myeloid cell leukemia protein 1 (Mcl-1). Mcl-1 shows up in large amounts in B cell type cancers. It is thought that blocking Mcl-1may stop the growth of B cell type cancers or enable other drugs to work more effectively.
This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.
OPEN TO ACCRUAL